Literature DB >> 26392970

Adoption of revised dosage recommendations for childhood tuberculosis in countries with different childhood tuberculosis burdens.

A K Detjen1, C Macé1, C Perrin1, S M Graham2, M Grzemska3.   

Abstract

BACKGROUND AND
OBJECTIVE: In 2010, the World Health Organization (WHO) published revised dosage recommendations for the treatment of tuberculosis (TB) in children. The aim of the survey was to assess whether countries adopt these new dosage recommendations, as well as to identify challenges in the management and treatment of childhood TB. In addition, countries were asked to provide 2010 surveillance data on childhood TB.
DESIGN: A survey questionnaire was developed and broadly disseminated to National Tuberculosis Programmes or people with close links to them.
RESULTS: Among the 34 countries that responded to the survey, the proportion of total national TB caseload reported in children in 2010 ranged from 0.67% to 23.6%. The data on new cases reported to this survey varied from data provided to the WHO global TB database. Most countries had childhood TB guidelines in place, and half had adopted the new dosage recommendations. Countries reported a number of challenges related to the implementation of the new recommendations and general management of childhood TB.
CONCLUSIONS: Despite the adoption of the new dosage recommendations, their implementation is complicated by the lack of appropriate fixed-dose combinations. In addition, accurate and consistent estimates of the global burden of childhood TB remained a major challenge. Technical assistance and support to countries is needed to improve childhood TB activities.

Entities:  

Keywords:  anti-tuberculosis medicines; childhood TB; disease burden; guidelines

Year:  2012        PMID: 26392970      PMCID: PMC4463065          DOI: 10.5588/pha.12.0052

Source DB:  PubMed          Journal:  Public Health Action        ISSN: 2220-8372


  6 in total

1.  Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Authors:  S Thee; J A Seddon; P R Donald; H I Seifart; C J Werely; A C Hesseling; B Rosenkranz; S Roll; K Magdorf; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

2.  Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.

Authors:  H S Schaaf; D P Parkin; H I Seifart; C J Werely; P B Hesseling; P D van Helden; J S Maritz; P R Donald
Journal:  Arch Dis Child       Date:  2005-06       Impact factor: 3.791

3.  Childhood tuberculosis in Malawi: nationwide case-finding and treatment outcomes.

Authors:  A D Harries; N J Hargreaves; S M Graham; C Mwansambo; P Kazembe; R L Broadhead; D Maher; F M Salaniponi
Journal:  Int J Tuberc Lung Dis       Date:  2002-05       Impact factor: 2.373

4.  Supplying quality-assured child-friendly anti-tuberculosis drugs to children.

Authors:  Robert P Gie; Robert H Matiru
Journal:  Int J Tuberc Lung Dis       Date:  2009-03       Impact factor: 2.373

5.  Closing the policy-practice gap in the management of child contacts of tuberculosis cases in developing countries.

Authors:  Philip C Hill; Merrin E Rutherford; Rick Audas; Reinout van Crevel; Stephen M Graham
Journal:  PLoS Med       Date:  2011-10-11       Impact factor: 11.069

6.  Antituberculosis drug-induced hepatotoxicity in children.

Authors:  Peter R Donald
Journal:  Pediatr Rep       Date:  2011-06-16
  6 in total
  6 in total

1.  Economic impact of thermostable vaccines.

Authors:  Bruce Y Lee; Patrick T Wedlock; Leila A Haidari; Kate Elder; Julien Potet; Rachel Manring; Diana L Connor; Marie L Spiker; Kimberly Bonner; Arjun Rangarajan; Delphine Hunyh; Shawn T Brown
Journal:  Vaccine       Date:  2017-04-25       Impact factor: 3.641

2.  Outcomes in children treated for tuberculosis with the new dispersible fixed-dose combinations in Port Moresby.

Authors:  V Apis; M Landi; S M Graham; T Islam; J Amini; G Sabumi; A M Mandalakas; T Meae; P du Cros; H D Shewade; H Welch
Journal:  Public Health Action       Date:  2019-09-21

3.  Short intensified treatment in children with drug-susceptible tuberculous meningitis.

Authors:  Anna Turkova; James A Seddon; Andrew J Nunn; Diana M Gibb; Patrick P J Phillips
Journal:  Pediatr Infect Dis J       Date:  2014-09       Impact factor: 2.129

4.  Understanding Market Size and Reporting Gaps for Paediatric TB in Indonesia, Nigeria and Pakistan: Supporting Improved Treatment of Childhood TB in the Advent of New Medicines.

Authors:  Renia Coghlan; Elizabeth Gardiner; Farhana Amanullah; Chikwe Ihekweazu; Rina Triasih; Malgorzata Grzemska; Charalambos Sismanidis
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

5.  Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial.

Authors:  Chishala Chabala; Anna Turkova; Margaret J Thomason; Eric Wobudeya; Syed Hissar; Vidya Mave; Marieke van der Zalm; Megan Palmer; Monica Kapasa; Perumal K Bhavani; Sarath Balaji; Priyanka A Raichur; Anne-Marie Demers; Graeme Hoddinott; Ellen Owen-Powell; Aarti Kinikar; Philippa Musoke; Veronica Mulenga; Rob Aarnoutse; Helen McIlleron; Anneke Hesseling; Angela M Crook; Mark Cotton; Diana M Gibb
Journal:  Trials       Date:  2018-04-19       Impact factor: 2.279

6.  Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations.

Authors:  Chishala Chabala; Anna Turkova; Anneke C Hesseling; Kevin M Zimba; Marieke van der Zalm; Monica Kapasa; Megan Palmer; Maxwell Chirehwa; Lubbe Wiesner; Eric Wobudeya; Aarti Kinikar; Vidya Mave; Syed Hissar; Louise Choo; Kristen LeBeau; Veronica Mulenga; Robb Aarnoutse; Diana Gibb; Helen McIlleron
Journal:  Clin Infect Dis       Date:  2022-05-30       Impact factor: 20.999

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.